Supplementary
CD3 20.6 (± 3.4) 20.8 (± 6.0) 20.7 (± 17.0) 33.8 (± 8.0) 51.9 (± 22.5) 49.2 (± 9.8) 37.7 (± 17.5) 61.5 (± 13.2) 29.8 (± 9.8)* CD4 13.7 (± 3.0) 14.0 (± 5.0) 16.2 (± 12.8) 27.3 (± 6.6) 41.2 (± 20.4) 39.5 (± 7.9) 28.5 (± 16.2) 34.9 (± 12.3) 14.1 (± 6.6) CD8 8.0 (± 0.9) 8.4 (± 1.9) 7.9 (± 6.1) 7.1 (± 1.8) 11.2 (± 2.8) 10.3 (± 2.8) 9.9 (± 1.1) 24.9 ( After bone marrow transplantation of BCR-ABL expressing or control cells the mice were treated for 9 days with vehicle or 20 mg/kg dasatinib and the peripheral blood was analyzed by FACS for the expression of Gr-1 (granulocytes), Ter119 (erythroid cells) and CD41 (megakaryocytic cells), gated on all living cells. The lymphocytes (FSC low /SSC low ) were further characterized by the expression of CD3, CD4 and CD8 (T cells) and B220 (B cells). All data are shown as mean ± SD. *p < 0.05.
